ATI Inc. (ATI) Q4 2025 earnings review
Record Margins Mask Flat Top-Line Growth
ATI delivered a masterclass in margin expansion despite a stagnant top line. While Q4 revenue was effectively flat year-over-year (+0.4%), Adjusted EBITDA surged 11% and margins expanded to 19.7%. The strategic pivot to Aerospace & Defense is paying off—A&D now constitutes 68% of sales. However, the divergence between GAAP Net Income (-30%) and Adjusted figures highlights significant noise from pension and restructuring charges. FY26 guidance is aggressive, targeting ~$1 billion in EBITDA, implying the company believes the volume pause is temporary.
🐂 Bull Case
ATI achieved 19.7% Adjusted EBITDA margins in Q4, significantly up from 17.9% a year ago. HPMC segment margins hit 24.0%. FY26 guidance implies continued expansion, proving the mix shift to high-value jet engine alloys is structurally accretive.
FY25 Adjusted Free Cash Flow jumped 53% YoY to $380M. Management is guiding for further acceleration to $430M-$490M in FY26, supporting continued aggressive buybacks ($470M repurchased in FY25).
🐻 Bear Case
Despite the narrative of robust demand, Q4 revenue was essentially flat (+0.4% YoY). The AA&S segment actually shrank 1%. If pricing power fades or volume doesn't materialize, the growth story collapses.
GAAP Net Income fell 30% YoY in Q4 due to pension remeasurement losses ($18.6M) and restructuring charges ($22.9M). Reliance on 'Adjusted' metrics is high; 'transformation costs' are becoming a recurring theme.
⚖️ Verdict: 🟢
Bullish. While the lack of revenue growth is a watch item, the profitability gains are undeniable. Generating 11% EBITDA growth on flat sales demonstrates immense pricing power and operational efficiency. FY26 guidance of ~16% EBITDA growth suggests management sees volume returning to match the margins.
Key Themes
Aerospace & Defense Mix Shift
The transformation is working. A&D sales reached 68% of total revenue in Q4, up from 65% a year ago. Commercial jet engine sales rose 7.5% YoY to $460M. This mix shift is the primary engine behind the margin expansion, isolating ATI from weaker industrial markets.
Advanced Alloys (AA&S) Stagnation
While the HPMC segment shines, the AA&S segment is struggling for growth. Q4 sales fell 1% YoY to $531M, driven by declines in medical, defense, and industrial products. Margins improved to 18.5% solely due to pricing/costs, but the volume decline indicates weakness in the broader industrial economy.
Aggressive Capital Returns
ATI is actively shrinking its share count. The company repurchased $470M in stock during FY25, significantly outpacing its Adjusted Free Cash Flow of $380M. With net debt reduction continuing (repaid $150M in Q4), the balance sheet supports maintaining this pace.
Restructuring & Pension Noise
Q4 results were messy on a GAAP basis. The company took a $22.9M pre-tax charge for 'transformation-related costs' and a $18.6M pension remeasurement loss. Investors should monitor if these 'special items' persist, as they obscure true economic earnings.
Other KPIs
Accelerating. Up from 17.9% in 24Q4. HPMC margins led the way at 24.0% (vs 20.0% prior year). This confirms the thesis that ATI's exits from low-margin product lines are permanently lifting the profitability floor.
Improving. Managed working capital as a percentage of annualized sales dropped to 32.5% from 36.4% in Q3. This is a critical improvement, releasing cash and indicating better supply chain fluidity.
Accelerating. Up 53% from $248M in FY24. The conversion of EBITDA to cash is improving, largely driven by the working capital improvements noted above.
Guidance
Accelerating. The midpoint ($1.0B) implies ~16% growth over FY25's $859M. This suggests management expects the flat revenue trend in Q4 to reverse, coupled with sustained margin performance.
Accelerating. Midpoint represents a ~21% increase over FY25. This indicates capital expenditures ($260M-$280M in 2025, likely similar in 2026) are stabilizing while operating cash flow grows.
Stable. The midpoint ($221M) represents ~13.5% YoY growth vs 25Q1 ($195M), continuing the double-digit profit growth trend despite Q4's revenue flatness.
Key Questions
The Revenue Disconnect
With Q4 revenue essentially flat year-over-year, specifically where is the volume growth coming from to support the +16% EBITDA growth implied in FY26 guidance? Is it purely pricing?
AA&S Segment Health
AA&S revenue declined year-over-year. Is this purely a function of exiting low-margin industrial products, or a signal of weakening demand in the broader economy (medical/industrial)?
Transformation Costs
We saw $22.9M in transformation costs in Q4. When does the 'transformation' officially end, allowing GAAP earnings to converge with Adjusted earnings?